Jade Biosciences licenses monospecific antibodies from Paragon for up to $22M in milestones

Jade Biosciences, Inc.

Paragon grants exclusive worldwide license to undisclosed target antibodies for all human therapeutic areas.
Jade pays up to $22M in development/regulatory milestones; $1.5M already paid for candidate nomination.
Additional sublicensing fees up to ~$20.1M on commercial milestones; royalties low to mid-single-digit.
Paragon restricted from generating monospecific antibodies targeting same target for at least 5 years.
Jade can terminate on 60 days' notice; agreement subject to standard termination provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.